Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fortis Therapeutics Inc.

Latest From Fortis Therapeutics Inc.

Deal Watch: Allergan, Celgene, AstraZeneca Among Biopharmas Advancing Existing Partnerships

Recent deal-making has seen new developments to further existing agreements, including Allergan licensing a depression candidate from the spinout of a company it bought in 2015. Also, updates on deals involving Celgene, AstraZeneca and Daiichi Sankyo.

Deals Business Strategies

Venture Funding Deals: New Cash For Delinia, Peloton, Fortis & Others

Moderna and Intarcia lead recent fundraisings; big pharma backing includes Novartis leading Series A for Inflazome and Pfizer for diabetes play Antolrx. Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced August through September 2016.

StartUps and SMEs Financing

VC Roundup: Early-Stage Funding Slips Again In Third Quarter, Plus 15 New Financings

Early-stage venture capital funding continues to decline, but corporate VC dollars and other sources of cash are emerging to fund startups. Also, biopharma companies raised $436.3m in 15 recent financings.

StartUps and SMEs Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Fortis Therapeutics Inc.
  • Senior Management
  • Jay Lichter, Pres. & CEO
    Tighe Reardon, CFO
    Marc Nasoff, PhD, CSO
  • Contact Info
  • Fortis Therapeutics Inc.
    11099 North Torrey Pines Rd., Ste. 290
    c/o COI
    La Jolla, CA 92037
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register